Clinical trialNCT03028350CompletedPhase 2Interventional

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

SponsorCumberland PharmaceuticalsEnrollment54Asthma, Aspirin-Induced

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other nonsteroidal anti-inflammatory drugs.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew White, MD
Scripps Research Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner University of Arizona Medical Center, Asthma & Airway Disease Research Center
Tucson, Arizona, United States
Antelope Valley Clinical Trials
Lancaster, California, United States
Scripps Clinic - Carmel Valley
San Diego, California, United States
Stanford University Medical Center
Stanford, California, United States
the Research Center
Hialeah, Florida, United States
Emory University School of Medicine, Sinus, Nasal, and Allergy Center
Atlanta, Georgia, United States
Deaconess Clinic
Evansville, Indiana, United States
Kansas City Allergy and Asthma Associates, Pa
Overland Park, Kansas, United States
Advanced Ent & Allergy
Louisville, Kentucky, United States
Rochester Regional Health
Rochester, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Ut Southwestern Medical Center
Dallas, Texas, United States
University of Virginia Medical Center
Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IfetrobanPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Jul 2017
Primary completion: 25 Apr 2023
Completion: 25 Apr 2023
Last update posted: 10 Jul 2024
Registered enrollment: 54
Registry id: NCT03028350

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.